贝伐单抗联合顺铂腹腔灌注治疗恶性腹水疗效观察  

Observation of bevacizumab combined with cisplatin intraperitoneal perfusion in the treatment of malignant ascites

作　　者：黄晓娟[1] 宫兆华[2] 陈剑[1] 孙等军[1] 耿冬梅[1] 成瑜[1] 孙萍[2] 张良明[1] 

机构地区：[1]青岛大学医学院附属烟台毓璜顶医院肿瘤内一科,山东烟台264000 [2]青岛大学医学院附属烟台毓璜顶医院肿瘤内二科,山东烟台264000

出　　处：《中国医药科学》2013年第5期20-21,105,共3页China Medicine And Pharmacy

摘　　要：目的探讨贝伐单抗联合顺铂腹腔灌注治疗恶性腹水近期疗效及不良反应。方法将34例恶性腹水患者分成2组,治疗组18例,予贝伐单抗(安维汀)5mg/kg联合顺铂60mg/m2,腹腔灌注,第1天;对照组16例,予顺铂60mg/m2,腹腔灌注,第1天。每4周重复,2～3疗程后评价疗效。结果贝伐单抗联合顺铂治疗组CR7例,PR8例,NC/PD3例,ORR为83.3%;对照组CR2例,PR5例,NC/PD9例,ORR为43.8%。治疗组生活质量改善率为88.9%,对照组为56.3%两组患者不良反应以Ⅰ～Ⅱ度骨髓抑制及胃肠道反应为主。结论与传统顺铂单药相比,贝伐单抗联合顺铂组显著提高恶性腹水患者客观缓解率,生活质量明显改善且安全性好,值得进一步临床验证。Objective To observe the effect and side-effects of bevacizumab combined with cisplatin intraperitoneal perfusion in the treatment of malignant ascites. Methods 34 patients with malignant ascites were randomly divided into two groups of bevacizumab/cisplatin group（18 cases ）and cisplatin group（16 cases）. Each patient received two or three cycles therapy of intraperitoneal perfusion. Results Bevacizumab/cisplatin group had CR 7 cases, PR 8 cases, NC/PD 3 cases, ORR 83.3%. Cisplatin group had CR 2 cases, PR 5 cases, NC/PD 9 cases, ORR 43.8%. The quality of life improved rate of two groups was 88.9%（bevacizumab/cisplatin）, 56.3% （ cisplatin ）.The side-effects of two groups were mainly I-II degree myelosuppression and gastrointestinal discomfort. Conclusion The treatment group（bevacizumab/cisplatin） significantly increases objective response rate of patients with malignant ascites and their quality of life can be improved obviously also. It deserves further study.

关 键 词：贝伐单抗 顺铂 恶性腹水 腹腔灌注 

分 类 号：R730.53[医药卫生—肿瘤]